Y
Yanxia Guo
Researcher at Janssen Pharmaceutica
Publications - 17
Citations - 2430
Yanxia Guo is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Immune system & T cell. The author has an hindex of 13, co-authored 15 publications receiving 1960 citations. Previous affiliations of Yanxia Guo include Chinese Academy of Sciences & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Molecular mechanism and function of CD40/CD40L engagement in the immune system.
TL;DR: The essential role CD40 plays in adaptive immunity is underscored and a wide spectrum of molecular and cellular processes is regulated by CD40 engagement including the initiation and progression of cellular and humoral adaptive immunity.
Journal ArticleDOI
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Lili Wang,Rotem Rubinstein,Janet Louise Lines,Anna Wasiuk,Cory L. Ahonen,Yanxia Guo,Li-Fan Lu,David C. Gondek,Yan-Yan Wang,Roy A. Fava,Andras Fiser,Steve C. Almo,Randolph J. Noelle,Randolph J. Noelle +13 more
TL;DR: VISTA suppresses T cell proliferation and cytokine production and can influence autoimmunity and antitumor responses in mice.
Journal ArticleDOI
A retinoic acid–dependent checkpoint in the development of CD4+ T cell–mediated immunity
Karina Pino-Lagos,Yanxia Guo,Chrysothemis C. Brown,Matthew P. Alexander,Raul Elgueta,Kathryn A. Bennett,Victor C. de Vries,Elizabeth C. Nowak,Rune Blomhoff,Shanthini Sockanathan,Roshantha A.S. Chandraratna,Ethan Dmitrovsky,Randolph J. Noelle,Randolph J. Noelle +13 more
TL;DR: Immune cell activation induces concurrent temporal and spatial retinoic acid signaling, and CD4+ T cell–specific loss of RA signals reduces effector function, migration, and polarity.
Journal ArticleDOI
Retinoic acid: A key player in immunity
TL;DR: An overview of the recent discoveries of the role that vitamin A and its metabolite, retinoic acid (RA), play in the regulation of immune cells and how RA impacts on leukocyte growth, differentiation, and homing is presented.
Journal ArticleDOI
Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression.
Yanxia Guo,Alice M. Walsh,Mary Canavan,Mihir D. Wechalekar,Suzanne Cole,Xuefeng Yin,Brittney Scott,Mathew J. Loza,Carl Orr,Trudy McGarry,Michele Bombardieri,Frances Humby,Susanna Proudman,Costantino Pitzalis,Malcolm D. Smith,Joshua R. Friedman,Ian Anderson,Loui Madakamutil,Douglas J. Veale,Ursula Fearon,Sunil Nagpal +20 more
TL;DR: The expression of PD-1 was increased in early and established RA synovial tissue compared to normal and OA synovium, whereas that of its ligands, programmed death ligand-1 (PD-L1) and PD-L2, was increased at all the stages of RA disease progression, suggesting that agonistic PD1 antibody-based therapeutics may show efficacy in RA treatment and interception.